Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Response of low-grade oligodendroglial tumors to temozolomide.

Literature DB >> 15662968

Response of low-grade oligodendroglial tumors to temozolomide.

Thomas N Byrne¹.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2004 PMID： 15662968 DOI： 10.1007/s11060-004-5896-4

Source DB: PubMed Journal: J Neurooncol ISSN： 0167-594X Impact factor: 4.130

× No keyword cloud information.

10 in total

1. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis.

Authors: Y Ino; R A Betensky; M C Zlatescu; H Sasaki; D R Macdonald; A O Stemmer-Rachamimov; D A Ramsay; J G Cairncross; D N Louis
Journal: Clin Cancer Res Date: 2001-04 Impact factor: 12.531

2. Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma.

Authors: N A Paleologos; D R Macdonald; N A Vick; J G Cairncross
Journal: Neurology Date: 1999-09-22 Impact factor: 9.910

3. Phase II trial of temozolomide in patients with progressive low-grade glioma.

Authors: Jennifer A Quinn; David A Reardon; Allan H Friedman; Jeremy N Rich; John H Sampson; James M Provenzale; Roger E McLendon; Sridharan Gururangan; Darell D Bigner; James E Herndon; Nicholas Avgeropoulos; Jonathan Finlay; Sandra Tourt-Uhlig; Mary Lou Affronti; Brandon Evans; Valerie Stafford-Fox; Sara Zaknoen; Henry S Friedman
Journal: J Clin Oncol Date: 2003-02-15 Impact factor: 44.544

4. Long-term outcome of low-grade oligodendroglioma and mixed glioma.

Authors: J D Olson; E Riedel; L M DeAngelis
Journal: Neurology Date: 2000-04-11 Impact factor: 9.910

5. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.

Authors: O L Chinot; S Honore; H Dufour; M Barrie; D Figarella-Branger; X Muracciole; D Braguer; P M Martin; F Grisoli
Journal: J Clin Oncol Date: 2001-05-01 Impact factor: 44.544

6. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group.

Authors: G Cairncross; D Macdonald; S Ludwin; D Lee; T Cascino; J Buckner; D Fulton; E Dropcho; D Stewart; C Schold
Journal: J Clin Oncol Date: 1994-10 Impact factor: 44.544

7. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions.

Authors: K Hoang-Xuan; L Capelle; M Kujas; S Taillibert; H Duffau; J Lejeune; M Polivka; E Crinière; Y Marie; K Mokhtari; A F Carpentier; F Laigle; J M Simon; P Cornu; P Broët; M Sanson; J Y Delattre
Journal: J Clin Oncol Date: 2004-08-01 Impact factor: 44.544

8. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.

Authors: J G Cairncross; K Ueki; M C Zlatescu; D K Lisle; D M Finkelstein; R R Hammond; J S Silver; P C Stark; D R Macdonald; Y Ino; D A Ramsay; D N Louis
Journal: J Natl Cancer Inst Date: 1998-10-07 Impact factor: 13.506

9. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.

Authors: M J van den Bent; M J B Taphoorn; A A Brandes; J Menten; R Stupp; M Frenay; O Chinot; J M Kros; C C D van der Rijt; Ch J Vecht; A Allgeier; T Gorlia
Journal: J Clin Oncol Date: 2003-07-01 Impact factor: 44.544

10. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities.

Authors: Jan C Buckner; Dean Gesme; Judith R O'Fallon; Julie E Hammack; Scott Stafford; Paul D Brown; Roland Hawkins; Bernd W Scheithauer; Bradley J Erickson; Ralph Levitt; Edward G Shaw; Robert Jenkins
Journal: J Clin Oncol Date: 2003-01-15 Impact factor: 44.544